Top Page
Emyria Ltd
(Sydney:EMD)
Emyria Ltd (EMD) vs. iShares MSCI Australia ETF (EWA)
Emyria Ltd Business Overview & Revenue Model
Emyria Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.39M | 1.39M | 2.20M | 1.59M | 1.82M | 1.98M |
| Gross Profit | 24.48K | 24.48K | -167.55K | -3.32M | -4.41M | -1.58M |
| EBITDA | -2.39M | -2.39M | -13.03M | -6.69M | -8.03M | -4.49M |
| Net Income | -3.14M | -3.14M | -11.46M | -5.13M | -7.33M | -4.91M |
Balance Sheet | ||||||
| Total Assets | 6.62M | 6.62M | 5.43M | 10.16M | 8.25M | 9.06M |
| Cash, Cash Equivalents and Short-Term Investments | 3.57M | 3.57M | 1.57M | 2.73M | 3.88M | 6.53M |
| Total Debt | 613.50K | 613.50K | 1.72M | 1.27M | 632.70K | 949.70K |
| Total Liabilities | 1.31M | 1.31M | 3.00M | 3.37M | 1.93M | 1.88M |
| Stockholders Equity | 5.31M | 5.31M | 2.43M | 6.79M | 6.32M | 7.18M |
Cash Flow | ||||||
| Free Cash Flow | -2.72M | -2.72M | -4.44M | -7.01M | -7.46M | -4.60M |
| Operating Cash Flow | -2.70M | -2.70M | -4.28M | -3.77M | -5.43M | -3.94M |
| Investing Cash Flow | 81.07K | 81.07K | -1.38M | -3.23M | -2.03M | -661.39K |
| Financing Cash Flow | 4.63M | 4.63M | 4.50M | 5.86M | 4.81M | 7.44M |
Emyria Ltd Technical Analysis
Emyria Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | AU$15.10M | -3.26 | -27.84% | ― | 6.77% | -8.45% | |
55 Neutral | AU$75.17M | -8.24 | -8647.54% | ― | 25.98% | 22.10% | |
52 Neutral | AU$23.25M | -12.89 | -17.05% | ― | 28.91% | -1050.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$43.43M | -9.29 | -81.30% | ― | -36.68% | 79.41% | |
40 Underperform | AU$16.45M | -0.24 | -240.60% | ― | -48.41% | -7200.00% | |
40 Underperform | AU$84.39M | -11.89 | ― | ― | ― | ― |
Emyria Ltd Corporate Events
Emyria Ltd has announced the quotation of 322,976 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of November 7, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its growth initiatives, potentially impacting its market positioning and providing new opportunities for stakeholders.
Emyria Ltd has announced the cessation of 300,000 securities due to the expiry of options that were not exercised or converted by November 1, 2025. This development may affect the company’s capital structure and could have implications for its stakeholders, as it reflects changes in the company’s financial instruments.
Emyria Limited has reported significant growth in revenue and operational expansion in its quarterly activity report for September 2025. The company has expanded its agreement with Medibank to include insurer-funded access to its mental health treatment programs for PTSD and TRD in both Perth and Brisbane. This expansion marks the first national rollout of insured mental health treatment programs in Australia, demonstrating strong insurer confidence in Emyria’s care model. The company has also increased its workforce and treatment capacity to support growing demand, with plans to commence patient dosing in Brisbane by late Q4 2025. Emyria’s strategic partnerships and scalable model position it as a leader in evidence-based mental health care, with ongoing commercial momentum and broader national rollout plans.
Emyria Ltd has announced the quotation of 278,113 fully paid ordinary securities on the Australian Securities Exchange (ASX), following the exercise of options or conversion of other convertible securities. This move is expected to enhance the company’s financial flexibility and market presence, potentially impacting its operations and positioning within the healthcare sector.
Emyria Limited has announced the issuance of 845,979 new fully paid ordinary shares at an issue price of $0.05 per share, following the exercise of options. This move allows the shares to be traded immediately under the exemption provided by section 708A(5) of the Corporations Act 2001, enhancing liquidity and potentially strengthening the company’s financial position. The announcement signifies Emyria’s compliance with relevant legal provisions, ensuring transparency and adherence to corporate governance standards.
Emyria Ltd has announced the quotation of 2,524,780 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective from October 17, 2025. This move signifies a strategic step for Emyria in expanding its capital base, potentially enhancing its market position and providing additional resources to further its healthcare initiatives.
Emyria Limited has announced a significant expansion of its services with a new funding agreement from Medibank Private Ltd. This agreement will allow eligible patients to access Emyria’s mental health programs for TRD and PTSD at the new Empax Clinic in Brisbane, marking the company’s first insurer-backed services on Australia’s East Coast. This expansion is part of Emyria’s national growth strategy to address the mental health burden in Australia by providing affordable and coordinated treatment options. The collaboration with Medibank is expected to reduce financial barriers for patients and demonstrates the scalability of Emyria’s care model, positioning the company as a leader in evidence-based mental health care.
Emyria Ltd has announced its involvement in addressing Australia’s mental health crisis through the development of advanced therapies, including the use of MDMA and psilocybin in psychedelic-assisted psychotherapy. While these treatments show promise, they are subject to clinical trials to ensure safety and efficacy, and currently, no approved products exist. The announcement highlights Emyria’s commitment to innovative mental health solutions, although it also underscores the risks and uncertainties inherent in developing such treatments.
Emyria Limited announced its participation in a live investor webinar hosted by Sharewise, where key executives will discuss the company’s latest developments and strategic outlook. The webinar will cover Emyria’s unique positioning in delivering evidence-based treatments, national expansion plans, and growth strategy, providing stakeholders with insights into the company’s future directions.
Emyria Ltd has announced the quotation of 112,610 ordinary fully paid securities on the ASX, effective October 10, 2025. This move signifies the company’s strategic efforts to enhance its capital structure and potentially increase its market presence, which could have implications for its stakeholders and industry positioning.
Emyria Ltd, a company listed on the ASX under the ticker EMD, is making significant strides in addressing serious mental illnesses. The company’s efforts are positively impacting the lives of patients and their communities, as highlighted by Executive Chairman Greg Hutchinson. This mission-driven approach underscores Emyria’s commitment to improving mental health outcomes.
Emyria Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement confirms the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, indicating a commitment to transparency and accountability in its management and oversight practices.
Emyria Ltd has announced its upcoming Annual General Meeting (AGM) for shareholders, scheduled for November 13, 2025, in West Perth, Australia. The company has opted for electronic distribution of the meeting materials, encouraging shareholders to vote by proxy if unable to attend in person. This move reflects a modern approach to shareholder engagement, potentially enhancing participation and operational efficiency.
Emyria Ltd has announced its Annual General Meeting (AGM) scheduled for November 13, 2025, at Stantons International in West Perth, Australia. The AGM will address the company’s annual report and include resolutions on the remuneration report and the election of Dr. Michael Winlo as a director. Shareholders are encouraged to participate and vote, with the meeting set to discuss key governance and strategic decisions impacting the company’s future direction.
Emyria Ltd announced the cessation of 75,000 securities due to the expiry of options or other convertible securities without exercise or conversion, effective October 7, 2025. This cessation of securities may impact the company’s capital structure and could have implications for stakeholders, particularly those holding or interested in these specific securities.
Emyria Ltd has announced a new issuance of 315,612 ordinary fully paid securities, which will be quoted on the ASX under the code EMD. This move is part of the company’s strategy to capitalize on convertible securities being exercised, potentially enhancing its financial position and market presence.
Emyria Ltd has announced a change in the director’s interest, specifically involving Mr. Greg Hutchinson. The change involves the acquisition of 10,663,691 unlisted options exercisable at $0.05 each, expiring on 22 March 2027. These options were issued as Loyalty Options to eligible shareholders, as per the company’s prospectus dated 8 September 2025. This move is part of Emyria’s strategy to reward its shareholders and potentially strengthen its market position by aligning the interests of its directors with those of its investors.
Emyria Ltd has announced the quotation of 516,616 new ordinary fully paid securities on the Australian Securities Exchange (ASX) as of September 30, 2025. This move is part of the company’s strategy to enhance its market presence and potentially increase its capital for future growth initiatives, reflecting its commitment to expanding its operations and influence in the healthcare sector.
Emyria Ltd has announced the issuance of 164,954,976 unquoted equity securities in the form of options with an exercise price of $0.05, set to expire on March 22, 2027. This issuance is part of a previously announced transaction and is not intended to be quoted on the ASX, indicating a strategic move to potentially raise capital or incentivize stakeholders without immediate market exposure.
Emyria Ltd announced the cessation of 150,000 securities due to the expiry of options or other convertible securities without exercise or conversion. This development may influence the company’s capital structure and could have implications for current and potential investors as it reflects changes in the company’s issued capital.
Emyria Limited has entered into a landmark multi-year agreement with Medibank Private Ltd to fund its Treatment-Resistant Depression (TRD) program at Perth Clinic. This agreement marks the first time a major Australian health insurer will fund a psychotherapy-led TRD program, significantly reducing financial barriers for eligible patients. This initiative builds on Medibank’s existing support for Emyria’s PTSD treatment program and further validates Emyria’s psychiatrist-led care model. With two funded programs now operational, Emyria is well-positioned for scalable growth and to make a lasting impact on mental health care in Australia.
Emyria Limited has successfully completed the sale of less than marketable parcels of shares to a consortium of specialist life sciences investors, achieving a 6.38% premium on the last traded share price. This strategic move not only validates Emyria’s growth trajectory and expansion strategy but also streamlines its shareholder register, reducing administrative costs and enhancing corporate efficiencies. The participation of strategic investors strengthens Emyria’s shareholder base and aligns with its goal to scale access to evidence-based mental health treatments across Australia.
Emyria Limited has announced a pro-rata bonus offer of unquoted Loyalty Options to incentivize eligible shareholders, providing them with an opportunity to participate in the company’s potential future success. The offer is limited to shareholders with registered addresses in Australia and New Zealand, excluding those outside these regions due to logistical and regulatory considerations.
Emyria Ltd has announced a pro-rata bonus offer of unquoted Loyalty Options to reward eligible shareholders, providing them with an opportunity to participate in the company’s future success. The offer, which involves issuing one Loyalty Option for every four shares held, aims to incentivize shareholder loyalty and facilitate secondary trading of shares issued upon the exercise of these options.
Emyria Ltd has announced a bonus issue of up to 166,040,206 unquoted Loyalty Options to eligible shareholders, with each option having an exercise price of $0.05. This issuance is part of a strategy to reward shareholders, with no action required from them to receive their options. The offer is speculative and is not available to investors outside Australia and New Zealand, which may impact the company’s shareholder engagement and market positioning.
Emyria Ltd has announced a change in the director’s interest in securities, with Mr. Greg Hutchinson acquiring additional shares and options. This change was facilitated through a director placement approved at a recent general meeting, indicating a strategic move to strengthen the company’s leadership stake and potentially enhance its market position.
Emyria Ltd has released a company update highlighting its focus on developing advanced therapies to address Australia’s mental health crisis. The announcement emphasizes the potential of MDMA and psilocybin in psychedelic-assisted psychotherapy, although these treatments are still undergoing clinical trials to assess their safety and efficacy. The release cautions about the risks associated with these compounds and notes that no products containing MDMA or psilocybin have been approved by the TGA for quality, safety, and efficacy. This development could impact Emyria’s operations and industry positioning as it seeks to innovate in mental health treatment.
Emyria Limited reported a significant reduction in its net loss for the year ended June 30, 2025, with a 73% decrease compared to the previous year, despite a 37% decline in revenue from customer sales and clinical services. The company’s financial statements received an unmodified audit opinion, indicating stability in its financial reporting, although no dividends were declared for the period.
Emyria Limited has scheduled its 2025 Annual General Meeting for November 13, 2025, in West Perth, Australia. A key agenda item will be the re-election of directors, with nominations closing on September 25, 2025. This meeting is crucial for stakeholders as it will address leadership roles within the company, potentially impacting its strategic direction and operations.
Emyria Limited has announced an investor webinar scheduled for August 28, 2025, where the company’s Executive Chairman, Greg Hutchinson, and management will provide a company update. This event is part of Emyria’s ongoing efforts to engage with stakeholders and provide insights into their operations and future plans. The announcement underscores Emyria’s commitment to transparency and stakeholder engagement, which could positively impact its industry positioning and investor relations.
Emyria Limited is expanding its Perth clinic to meet the growing demand for PTSD treatments, supported by a landmark agreement with Medibank Private Ltd. This expansion marks the first time psychedelic-assisted care is covered by private health insurance in Australia, validating Emyria’s clinical protocols and providing a scalable reimbursement pathway. The company is also preparing for its first interstate expansion in Brisbane, partnering with Avive Health to establish a national network of clinics. This strategic move positions Emyria as a first-mover in an emerging sector, with the potential to support predictable, recurring revenues and strengthen its partnerships with insurers, hospitals, and regulators.
Emyria Ltd announced that all resolutions presented at its General Meeting of Shareholders were approved by a poll. The resolutions included ratifications and approvals for the issuance of shares and options, which are likely to impact the company’s capital structure and support its strategic initiatives. This outcome reflects shareholder support for Emyria’s ongoing projects and could enhance its market positioning.